All In Biotech

Drug Trial Radar · NCT07028320

To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk

A Multicenter, Randomized, Open-label, Parallel Controlled, Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of SAL056 (Teriparatide for Injection ) in the Treatment of Postmenopausal Women With Osteoporosis at High Fracture Risk

Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 493 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

493

Actual

Start

Dec 3, 2021

Primary completion

Dec 30, 2023

Study completion May 20, 2024

Sponsor

Sponsor type
Industry
First posted
Jun 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 45 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women with Osteoporosis at High Fracture Risk

Conditions

  • Postmenopausal Women With Osteoporosis

Interventions

  • SAL056 (56.5μg)Drug

    Administered by subcutaneous injection once a week during treatment phase

  • AlendronateDrug

    70 mg tablet taken once a week during treatment phase

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Bone Mineral Density (BMD) of Lumbar Spine from Baseline to 48 WeeksTime frame: Baseline to 48 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Sixth People's Hosptital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.